Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Unknown 3Recruiting 2Terminated 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Genitourinary 3

Conditions

Breast Neoplasms 1275Carcinoma, Non-Small-Cell Lung 783Neoplasms 767Colorectal Neoplasms 755Carcinoma, Hepatocellular 579Stomach Neoplasms 578Prostatic Neoplasms 501Lung Neoplasms 461Pancreatic Neoplasms 416Rectal Neoplasms 331Recurrence 312Neoplasm Metastasis 305Leukemia, Myeloid, Acute 289Multiple Myeloma 281Colonic Neoplasms 280Lymphoma 273Uterine Cervical Neoplasms 269Esophageal Neoplasms 267Ovarian Neoplasms 261Head and Neck Neoplasms 246Melanoma 240Precursor Cell Lymphoblastic Leukemia-Lymphoma 209Brain Neoplasms 195Lymphoma, Large B-Cell, Diffuse 184Nasopharyngeal Carcinoma 180Lymphoma, Non-Hodgkin 173Leukemia 173Liver Neoplasms 163Glioblastoma 158Urinary Bladder Neoplasms 153

Interventions

toripalimab 1tislelizumab 1liposomal doxorubicin 1disitamab vedotin 1RC48 antibody 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Unknown × Interventional × Muscle Invasive Bladder Cancer × Clear all
NCT05979740 2023-08-31

RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC

RenJi Hospital

Phase 2 Unknown
6 enrolled
Genitourinary

Muscle Invasive Bladder Cancer

NCT04813107 2022-02-22

ANTICIPATE

Jiangsu Yahong Meditech Co., Ltd aka Asieris

Phase 1/2 Unknown
79 enrolled
Genitourinary

Muscle Invasive Bladder Cancer

NCT04101812 2019-09-26

Pegylated Liposomal Doxorubicin, PD-1 in Treating Muscle Invasive Bladder Cancer

Tianjin Medical University Second Hospital

Phase 2 Unknown
60 enrolled
Genitourinary

Muscle Invasive Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡